Paper29438696
The Integrated Genomic Landscape of Thymic Epithelial Tumors.
Radovich M and 47 others. Cancer Cell, 2018. Cited by 326 papers, by iCite.
Cite this record
ConductScience Library. The Integrated Genomic Landscape of Thymic Epithelial Tumors. Papers, record 29438696. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29438696
- Disease
- thymic carcinoma49 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Mutation | Major topic |
| Neoplasms, Glandular and Epithelial | Major topic |
| Thymoma | Major topic |
| Thymus Neoplasms | Major topic |
| Transcription Factors, TFII | Major topic |
| Adolescent | |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Female | |
| Genomics | |
| Humans | |
| Male | |
| Middle Aged | |
| Young Adult |
Source PubMed
Grants26
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| U24 CA143882 | NCI NIH HHS | United States | U24CA143882 | PubMed and NIH | NIH RePORTER |
| U24 CA143866 | NCI NIH HHS | United States | U24CA143866 | PubMed and NIH | NIH RePORTER |
| R01 HG007069 | NHGRI NIH HHS | United States | R01HG007069 | PubMed and NIH | NIH RePORTER |
| U54 HG003273 | NHGRI NIH HHS | United States | U54HG003273 | PubMed | NIH RePORTER |
| U24 CA143840 | NCI NIH HHS | United States | U24CA143840 | PubMed and NIH | NIH RePORTER |
| U24 CA143843 | NCI NIH HHS | United States | U24CA143843 | PubMed and NIH | NIH RePORTER |
| U24 CA143858 | NCI NIH HHS | United States | U24CA143858 | PubMed | NIH RePORTER |
| U24 CA143848 | NCI NIH HHS | United States | U24CA143848 | PubMed and NIH | NIH RePORTER |
| U24 CA210949 | NCI NIH HHS | United States | U24CA210949 | PubMed and NIH | NIH RePORTER |
| U24 CA143867 | NCI NIH HHS | United States | U24CA143867 | PubMed and NIH | NIH RePORTER |
| U24 CA210990 | NCI NIH HHS | United States | U24CA210990 | PubMed and NIH | NIH RePORTER |
| U24 CA211000 | NCI NIH HHS | United States | U24CA211000 | PubMed and NIH | NIH RePORTER |
| P30 ES010126 | NIEHS NIH HHS | United States | P30ES010126 | PubMed and NIH | NIH RePORTER |
| P30 CA016672 | NCI NIH HHS | United States | P30CA016672 | PubMed and NIH | NIH RePORTER |
| U54 HG003067 | NHGRI NIH HHS | United States | U54HG003067 | PubMed and NIH | NIH RePORTER |
| U24 CA143835 | NCI NIH HHS | United States | U24CA143835 | PubMed and NIH | NIH RePORTER |
| U24 CA210950 | NCI NIH HHS | United States | U24CA210950 | PubMed and NIH | NIH RePORTER |
| U24 CA143845 | NCI NIH HHS | United States | U24CA143845 | PubMed and NIH | NIH RePORTER |
| U24 CA143799 | NCI NIH HHS | United States | U24CA143799 | PubMed and NIH | NIH RePORTER |
| P30 CA008748 | NCI NIH HHS | United States | P30CA008748 | PubMed and NIH | NIH RePORTER |
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT05832827 | First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis) | Results | ClinicalTrials.gov | |
| NCT07343453 | A Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan in Second-Line and Subsequent Treatments for Advanced Thymic Epithelial Tumors | Background | ClinicalTrials.gov |
References114
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23792059 | Autoimmune associations and autoantibody screening show focused recognition in patient subgroups with generalized myasthenia gravis. | Hum Immunol | 2013 | https://conductscience.org/library/papers/23792059 | PubMed |
| 2 | 17041095 | Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. | Mol Cancer Ther | 2006 | https://conductscience.org/library/papers/17041095 | PubMed |
| 3 | 23894276 | A gene signature to determine metastatic behavior in thymomas. | PLoS One | 2013 | https://conductscience.org/library/papers/23894276 | PubMed |
| 4 | 25405470 | RADIA: RNA and DNA integrated analysis for somatic mutation detection. | PLoS One | 2014 | https://conductscience.org/library/papers/25405470 | PubMed |
| 5 | 10443881 | Neurofilament is an autoantigenic determinant in myasthenia gravis. | Ann Neurol | 1999 | https://conductscience.org/library/papers/10443881 | PubMed |
| 6 | 25396314 | The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors. | J Thorac Oncol | 2014 | https://conductscience.org/library/papers/25396314 | PubMed |
| 7 | 18832364 | PID: the Pathway Interaction Database. | Nucleic Acids Res | 2009 | https://conductscience.org/library/papers/18832364 | PubMed |
| 8 | 1702196 | Absence of acetylcholine-induced current in epithelial cells from thymus glands and thymomas of myasthenia gravis patients. | Neurology | 1991 | https://conductscience.org/library/papers/1702196 | PubMed |
| 9 | 20935650 | De novo assembly and analysis of RNA-seq data. | Nat Methods | 2010 | https://conductscience.org/library/papers/20935650 | PubMed |
| 10 | 1333754 | Factors influencing the interaction of herpes simplex virus glycoprotein C with the third component of complement. | Arch Virol | 1992 | https://conductscience.org/library/papers/1333754 | PubMed |
| 11 | 24847446 | Novel biologic therapies for thymic epithelial tumors. | Front Oncol | 2014 | https://conductscience.org/library/papers/24847446 | PubMed |
| 12 | 11932250 | BLAT--the BLAST-like alignment tool. | Genome Res | 2002 | https://conductscience.org/library/papers/11932250 | PubMed |
| 13 | 27103470 | Myasthenia gravis - autoantibody characteristics and their implications for therapy. | Nat Rev Neurol | 2016 | https://conductscience.org/library/papers/27103470 | PubMed |
| 14 | 11920496 | Somatostatin analogs and prednisone in advanced refractory thymic tumors. | Cancer | 2002 | https://conductscience.org/library/papers/11920496 | PubMed |
| 15 | 25417114 | Integrated genomic characterization of papillary thyroid carcinoma. | Cell | 2014 | https://conductscience.org/library/papers/25417114 | PubMed |
| 16 | 22127579 | Finding consistent patterns: a nonparametric approach for identifying differential expression in RNA-Seq data. | Stat Methods Med Res | 2013 | https://conductscience.org/library/papers/22127579 | PubMed |
| 17 | 24871328 | A pan-cancer proteomic perspective on The Cancer Genome Atlas. | Nat Commun | 2014 | https://conductscience.org/library/papers/24871328 | PubMed |
| 18 | 25267794 | The Cancer Genomics Hub (CGHub): overcoming cancer through the power of torrential data. | Database (Oxford) | 2014 | https://conductscience.org/library/papers/25267794 | PubMed |
| 19 | 21816040 | RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. | BMC Bioinformatics | 2011 | https://conductscience.org/library/papers/21816040 | PubMed |
| 20 | 21906370 | Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. | Clin Proteomics | 2011 | https://conductscience.org/library/papers/21906370 | PubMed |
Cited by244
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 326 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42980878 | Integrative molecular profiling of TAM receptors and STAT-SOCS signaling in thymic epithelial tumors. | Med Oncol | 2026 | https://conductscience.org/library/papers/42980878 | PubMed |
| 42972561 | Promoter CpG island hypomethylation and overexpression of molecules homologous to the muscle autoantigens acetylcholine receptor and ryanodine receptor in thymoma epithelial cells associated with myasthenia gravis. | Clin Epigenetics | 2026 | https://conductscience.org/library/papers/42972561 | PubMed |
| 42873340 | Thymic epithelial tumors: what's next? | Cancer Metastasis Rev | 2026 | https://conductscience.org/library/papers/42873340 | PubMed |
| 42778290 | Ivonescimab plus chemotherapy as first-line treatment for advanced thymic carcinoma: preliminary results of a phase II trial with biomarker analyses. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/42778290 | PubMed |
| 42724295 | Immune checkpoint inhibitors in thymic epithelial tumors: current evidence, immune-related toxicity, and perioperative considerations-a narrative review. | J Thorac Dis | 2026 | https://conductscience.org/library/papers/42724295 | PubMed |
| 42589271 | Precision Oncology in Thymic Epithelial Tumors: Therapeutic Horizons and Implementation Barriers. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42589271 | PubMed |
| 42512415 | Palliative Systemic Therapy in Advanced Thymic Epithelial Tumors in 2026-A Narrative Review. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42512415 | PubMed |
| 42433331 | Clinical and Immunologic Features of Primary Enteric-Type Thymic Adenocarcinomas: A Rare Variant of a Rare Cancer. | JTO Clin Res Rep | 2026 | https://conductscience.org/library/papers/42433331 | PubMed |
| 42427482 | Mediastinal epithelial neoplasms with recurrent molecular alterations. | Mediastinum | 2026 | https://conductscience.org/library/papers/42427482 | PubMed |
| 42427471 | Evolving paradigms in thymoma surgery and multidisciplinary care: a narrative review. | Mediastinum | 2026 | https://conductscience.org/library/papers/42427471 | PubMed |
| 42363019 | Redefining therapeutic horizons in thymic epithelial tumors: precision, combinations, and emerging biology. | NPJ Precis Oncol | 2026 | https://conductscience.org/library/papers/42363019 | PubMed |
| 42194981 | Distinct Associations of GTF2I, TP53, and NOTCH1 Variants with Indolent and Aggressive Thymic Epithelial Tumors in Vietnamese Patients. | Genes (Basel) | 2026 | https://conductscience.org/library/papers/42194981 | PubMed |
| 42091897 | A single-cell atlas revealing cellular heterogeneity across healthy and diseased human thymus. | Nat Commun | 2026 | https://conductscience.org/library/papers/42091897 | PubMed |
| 41982620 | HER2 expression and HER2 gene amplification in thymic epithelial tumors: a narrative review. | Mediastinum | 2026 | https://conductscience.org/library/papers/41982620 | PubMed |
| 41982618 | Reframing thymic epithelial tumors through single-cell transcriptomics: a narrative review. | Mediastinum | 2026 | https://conductscience.org/library/papers/41982618 | PubMed |
| 41982608 | Oncologic strategies and options for the management of metastatic thymic carcinoma. | Mediastinum | 2026 | https://conductscience.org/library/papers/41982608 | PubMed |
| 41954343 | Distinction of thymic carcinoma and type B3 thymoma using ancillary biomarkers. | Pathologica | 2025 | https://conductscience.org/library/papers/41954343 | PubMed |
| 41870660 | Low GBX2 expression is associated with histological type B thymoma: a multi-omics analysis. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41870660 | PubMed |
| 41847153 | Brief Report: Androgen Receptor Expression Is Associated With Male Predominance in Thymic Neuroendocrine Neoplasms. | JTO Clin Res Rep | 2026 | https://conductscience.org/library/papers/41847153 | PubMed |
| 41843177 | Thymic epithelial tumors at the crossroads of immunity, autoimmunity, and immunotherapy. | Cancer Immunol Immunother | 2026 | https://conductscience.org/library/papers/41843177 | PubMed |
Genes37
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Drugs4
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| LENVATINIB | CHEMBL1289601 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1289601 | ChEMBL |
| CARBOPLATIN | CHEMBL1351 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1351 | ChEMBL |
| PEMBROLIZUMAB | CHEMBL3137343 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL3137343 | ChEMBL |
| PACLITAXEL | CHEMBL428647 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL428647 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29438696
GET https://conductscience.org/api/papers/v1/29438696/authors?page=2